Anzeige
Meldung des Tages: After-Hours Bombe: FUTR meldet Rekord-Dealer-Wachstum — Payments 2.0 zündet jetzt richtig

PTC Therapeutics News

Aktie
WKN:  A1W0MW ISIN:  US69366J2006 US-Symbol:  PTCT Branche:  Biotechnologie Land:  USA
70,44 $
+1,77 $
+2,58%
59,868 € 13.04.26
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
-
KGV
8,64
Index-Zuordnung
-

PTC Therapeutics News

21.08.25 - PR Newswire
PTC Therapeutics to Participate at Upcoming Investor Conferences
PTC Therapeutics to Participate at Upcoming Investor Conferences PR Newswire
19.08.25 - PR Newswire
PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA
PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA PR Newswire
07.08.25 - PR Newswire
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results PR Newswire
28.07.25 - PR Newswire
PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) PR Newswire
21.07.25 - PR Newswire
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results PR Newswire
23.06.25 - PR Newswire
Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU) PR Newswire
22.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
19.06.25 - PR Newswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
12.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
07.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
01.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
26.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
20.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
12.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
06.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
06.05.25 - PR Newswire
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results PR Newswire
05.05.25 - PR Newswire
PTC518 PIVOT-HD Study Achieves Primary Endpoint
PTC518 PIVOT-HD Study Achieves Primary Endpoint PR Newswire
01.05.25 - PR Newswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
25.04.25 - PR Newswire
PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) PR Newswire
24.04.25 - PR Newswire
PTC Therapeutics to Participate at Upcoming Investor Conferences
PTC Therapeutics to Participate at Upcoming Investor Conferences PR Newswire

Newssuche

Videos

newspaper
07.04.26 +5,47%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »